Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I)
slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients. Study
participants will be followed for 2 years once enrolled. They will receive either placebo or
the active IGF-I. Examinations will take place at approximately 6-month intervals.
Phase:
Phase 3
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
ALS Association Cephalon National Institute of Neurological Disorders and Stroke (NINDS)